BioMarin to Acquire Amicus Therapeutics in $4.8 Billion Deal, Bolstering Leadership in Rare Diseases and Driving Growth
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Bolstering Leadership in Rare Diseases, Driving Revenue Growth, and Enhancing Financial Outlook BioMarin Pharmaceutical Inc. and Amicus Therapeutics announced today that BioMarin…
WuXi Biologics Earns Top “A” Ratings from CDP for Climate Change and Water Security
WuXi Biologics Earns Top “A” Ratings from CDP for Climate Change and Water Security WuXi Biologics announced that it has been named to the CDP “A” lists for both Climate…
Merck Strikes Deal with U.S. Government to Broaden Medicine Access and Reduce Costs for Americans
Merck Strikes Deal with U.S. Government to Broaden Access to Medicines and Reduce Costs for Americans Merck, known as MSD outside of the United States and Canada, today announced a…
Johnson & Johnson Supports HRS Registry to Enhance Real-World Evidence in Pulsed Field Ablation (PFA)
Johnson & Johnson Supports HRS Registry to Enhance Real-World Evidence for PFA ohnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced its sponsorship of a new data…
BioNTech Completes Acquisition of CureVac N.V., Including Follow-on Offering, to Bolster Leadership in mRNA Innovation
BioNTech Completes Acquisition of CureVac N.V., Including Follow-on Offering Period, to Bolster Its Leading Position in the mRNA Space BioNTech SE today announced the closing of its acquisition of CureVac N.V…
Takeda’s Zasocitinib Shows Promise in Phase 3 Psoriasis Trial as Once-Daily Pill for Clear Skin
Takeda’s Zasocitinib Demonstrates Landmark Phase 3 Results in Plaque Psoriasis, Offering Hope for Clear Skin with a Once-Daily Oral Therapy and Ushering in a New Treatment Era Takeda today announced…
Johnson & Johnson Secures FDA Approval for TRUFILL n-BCA Liquid Embolic System to Treat Symptomatic Chronic Subdural Hematoma
Johnson & Johnson Secures FDA Approval for TRUFILL n-BCA Liquid Embolic System to Treat Symptomatic Chronic Subdural Hematoma Johnson & Johnson MedTech, a leader in neurovascular care, announced that the U.S.…
Novo Nordisk Seeks FDA Approval for CagriSema—First Once-Weekly Combination of GLP-1 and Amylin Analogues for Weight Management
Novo Nordisk Submits FDA Application for CagriSema—First Once-Weekly Combination of GLP-1 and Amylin Analogues for Weight Management Today, Novo Nordisk announced the submission of a New Drug Application (NDA) to…
Lilly’s Orforglipron Sustains Weight Loss After Switching from Injectable to Oral GLP-1 Therapy in Phase 3 Trial
Lilly’s Orforglipron Helps Sustain Weight Loss After Switching from Injectable to Oral GLP-1 Therapy in Pivotal Phase 3 Trial Eli Lilly and Company today announced positive topline results from the…
WHO Hosts Second Global Summit to Advance Evidence, Integration, and Innovation in Traditional Medicine
WHO Hosts Second Global Summit to Advance Evidence, Integration, and Innovation in Traditional Medicine The World Health Organization (WHO)’s Second Global Summit on Traditional Medicine, jointly organized with the Government of…
Incyte Announces EC Approval of Minjuvi® (Tafasitamab) for Relapsed or Refractory Follicular Lymphoma
Incyte Announces EU Approval of Minjuvi® for R/R Follicular Lymphoma Incyte today announced that the European Commission (EC) has approved Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult…
Alnylam to Invest $250M in U.S. Facility for Enzymatic Ligation Platform
Alnylam to Invest $250M in Enzymatic Ligation Platform at U.S. Facility to Meet Global RNAi Demand Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced the planned expansion of…